To determine whether the regular administration of the beta-blocker drug propranolol to
people who had had at least one documented myocardial infarction would result in a
significant reduction of mortality from all causes over the follow-up period. Eligible
volunteer patients were recruited to participate in a double-blind clinical trial within 21
days after the onset of the acute event. One-half of the patients were randomly assigned to a
beta-blocking drug (propranolol) and one-half to a placebo. The trial also evaluated the
effect of propranolol on incidences of coronary heart disease mortality, sudden cardiac
death, and nonfatal myocardial infarction plus coronary heart disease mortality in persons
with documented previous myocardial infarction.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Propranolol
Criteria
Men and women, ages 30 to 69. Documented myocardial infarction.